|
| Preferred terms (PTs) | SOC | Case reports | ROR (95% CI) | PRR (95% CI) | IC (IC025) | EBGM (EBGM05) |
|
| Vitreoretinal traction syndrome | Eye disorders | 15 | 1108.22 (593.69–2068.67) | 1103.98 (592.36–2057.51) | 9.51 (7.63) | 727.97 (389.98) |
| Nitrituria | Renal and urinary disorders | 5 | 3561.82 (850.91–14909.47) | 3557.28 (850.4–14880.23) | 10.38 (6.97) | 1334.6 (318.83) |
| Human epidermal growth factor receptor negative | Investigations | 6 | 675.04 (269.45–1691.15) | 674.01 (269.33–1686.76) | 9 (6.34) | 512.49 (204.57) |
| Leiomyosarcoma recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 4 | 949.58 (292.3–3084.81) | 948.61 (292.25–3079.1) | 9.36 (6.11) | 657.04 (202.25) |
| Progesterone receptor assay positive | Investigations | 6 | 534.41 (218.33–1308.09) | 533.59 (218.23–1304.66) | 8.74 (6.13) | 427.07 (174.48) |
| Oestrogen receptor assay positive | Investigations | 6 | 400.81 (167.5–959.11) | 400.19 (167.43–956.56) | 8.4 (5.85) | 337.16 (140.9) |
| hER2 negative breast cancer | Reproductive system and breast disorders | 4 | 502.72 (169.08–1494.71) | 502.2 (169.06–1491.84) | 8.67 (5.63) | 406.74 (136.8) |
| Anhidrosis | Skin and subcutaneous tissue disorders | 13 | 257.77 (144.87–458.66) | 256.91 (144.63–456.36) | 7.84 (6.06) | 229.42 (128.93) |
| Breast cancer recurrent | Reproductive system and breast disorders | 64 | 165.3 (127.95–213.56) | 162.62 (126.37–209.27) | 7.24 (6.4) | 151.18 (117.02) |
| Pseudocirrhosis | Hepatobiliary disorders | 16 | 201.7 (120.7–337.07) | 200.88 (120.44–335.06) | 7.52 (5.91) | 183.69 (109.92) |
| Tongue cancer metastatic | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 4 | 341.85 (118.91–982.72) | 341.5 (118.9–980.8) | 8.2 (5.26) | 294.53 (102.46) |
| Oestradiol increased | Investigations | 9 | 218.79 (110.11–434.74) | 218.29 (110.01–433.12) | 7.63 (5.56) | 198.13 (99.71) |
| Joint neoplasm | Musculoskeletal and connective tissue disorders | 4 | 316.52 (110.7–905.02) | 316.2 (110.69–903.25) | 8.11 (5.19) | 275.53 (96.37) |
| Pelvic organ prolapse | Reproductive system and breast disorders | 6 | 233.19 (100.34–541.93) | 232.84 (100.31–540.48) | 7.71 (5.26) | 210.04 (90.38) |
| Soft tissue neoplasm | Musculoskeletal and connective tissue disorders | 5 | 254.41 (100.6–643.38) | 254.09 (100.58–641.89) | 7.83 (5.18) | 227.17 (89.83) |
| Carbohydrate antigen 15-3 increased | Investigations | 15 | 163.14 (96.42–276.03) | 162.51 (96.23–274.46) | 7.24 (5.6) | 151.09 (89.29) |
| Trigger finger | Musculoskeletal and connective tissue disorders | 58 | 124.64 (95.48–162.71) | 122.81 (94.43–159.72) | 6.86 (5.99) | 116.18 (89) |
| Vascular compression | Vascular disorders | 9 | 179.94 (91.07–355.52) | 179.53 (90.99–354.2) | 7.37 (5.32) | 165.67 (83.85) |
| Metastatic uterine cancer | Reproductive system and breast disorders | 4 | 230.98 (82.29–648.34) | 230.74 (82.28–647.06) | 7.7 (4.84) | 208.33 (74.22) |
| Metastases to thorax | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 6 | 171.01 (74.41–393.02) | 170.75 (74.38–391.96) | 7.31 (4.89) | 158.18 (68.82) |
| Vertebral column mass | Musculoskeletal and connective tissue disorders | 6 | 162.35 (70.75–372.54) | 162.1 (70.73–371.54) | 7.24 (4.83) | 150.73 (65.69) |
| Metastases to chest wall | Musculoskeletal and connective tissue disorders | 8 | 140.24 (68.54–286.97) | 139.96 (68.49–286) | 7.04 (4.9) | 131.41 (64.22) |
| Autoimmune pancreatitis | Immune system disorders | 10 | 127.37 (67.24–241.25) | 127.05 (67.18–240.27) | 6.91 (4.97) | 119.96 (63.33) |
| pIK3CA-activated mutation | Congenital, familial and genetic disorders | 7 | 132.45 (61.69–284.37) | 132.22 (61.66–283.5) | 6.96 (4.71) | 124.56 (58.02) |
| Metastases to abdominal wall | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 5 | 150.5 (60.74–372.92) | 150.31 (60.72–372.05) | 7.13 (4.56) | 140.48 (56.69) |
| Resorption bone increased | Metabolism and nutrition disorders | 6 | 128.26 (56.24–292.5) | 128.06 (56.22–291.7) | 6.92 (4.53) | 120.87 (53) |
| Breast cancer metastatic | Reproductive system and breast disorders | 94 | 67.75 (55.04–83.39) | 66.15 (54–81.03) | 6 (5.32) | 64.19 (52.15) |
| Diabetic hyperosmolar coma | Endocrine disorders | 6 | 124.52 (54.64–283.78) | 124.33 (54.62–283.02) | 6.88 (4.49) | 117.54 (51.58) |
| Metastases to bone | Musculoskeletal and connective tissue disorders | 143 | 63.74 (53.81–75.5) | 61.45 (52.19–72.35) | 5.9 (5.34) | 59.76 (50.45) |
| Cystoid macular oedema | Injury, poisoning and procedural complications | 28 | 74.95 (51.35–109.39) | 74.42 (51.13–108.34) | 6.17 (4.96) | 71.95 (49.3) |
| Metastases to lymph nodes | Blood and lymphatic system disorders | 54 | 65.42 (49.81–85.92) | 64.53 (49.32–84.44) | 5.97 (5.08) | 62.67 (47.72) |
| Labile hypertension | Vascular disorders | 4 | 135.65 (49.35–372.87) | 135.51 (49.35–372.12) | 6.99 (4.21) | 127.48 (46.38) |
| Vitreous adhesions | Eye disorders | 3 | 160.2 (49.54–518.07) | 160.08 (49.54–517.24) | 7.22 (4.13) | 148.98 (46.07) |
| dupuytren’s contracture | Musculoskeletal and connective tissue disorders | 11 | 86.56 (47.33–158.29) | 86.32 (47.28–157.59) | 6.38 (4.53) | 83 (45.39) |
| Clubbing | Cardiac disorders | 6 | 107.78 (47.44–244.88) | 107.61 (47.42–244.22) | 6.68 (4.31) | 102.5 (45.11) |
| Hyperparathyroidism primary | Metabolism and nutrition disorders | 5 | 114.9 (46.7–282.69) | 114.75 (46.69–282.03) | 6.77 (4.22) | 108.95 (44.28) |
| Lichen sclerosus | Skin and subcutaneous tissue disorders | 7 | 91.82 (43.06–195.79) | 91.66 (43.04–195.19) | 6.46 (4.24) | 87.93 (41.24) |
| Metastases to breast | Reproductive system and breast disorders | 5 | 104.76 (42.66–257.23) | 104.63 (42.66–256.62) | 6.64 (4.1) | 99.78 (40.64) |
| Hormone receptor positive breast cancer | Reproductive system and breast disorders | 6 | 91.61 (40.44–207.53) | 91.47 (40.43–206.97) | 6.46 (4.1) | 87.75 (38.74) |
| Retroperitoneal fibrosis | Immune system disorders | 7 | 83.61 (39.27–178.04) | 83.47 (39.25–177.5) | 6.33 (4.11) | 80.36 (37.74) |
|
